Chemotherapy-induced peripheral neuropathy.
OBJECTIVE
To review the literature documenting the scope, treatment, and prevention of chemotherapy-induced neuropathy.


METHODS
Published abstracts, primary research literature, and textbook chapters.


RESULTS
Recent improvements in the management of other treatment-related toxicities have led to peripheral neuropathy becoming a dose-limiting toxicity of commonly used chemotherapeutic groups such as platinols, vinca alkaloids, and taxanes.


CONCLUSIONS
The nervous system has not been the focus of education or training for oncology nurses. Therefore, nurses' ability to educate patients regarding this aspect of their condition has been limited.


CONCLUSIONS
With its significant impact on quality of life, peripheral neuropathy treatment and prevention are important components in the care of patients with cancer.
Armstrong
Terri
T
Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. tsarmstr@mdanderson.org
Almadrones
Lois
L
Gilbert
Mark R
MR
D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010353:Patient Education as Topic; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000451:nursing* / Q000503:physiopathology / Q000517:prevention & control; D011788:Quality of Life; D012307:Risk Factors
D000927:Anticonvulsants; D000928:Antidepressive Agents; D000970:Antineoplastic Agents